![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Understanding the Resistance Profile of the HIV-1 NNRTI
Doravirine in Combination With the Novel NRTTI MK-8591
|
|
|
Reported by Jules Levin
22nd International AIDS Conference; Amsterdam, The Netherlands; 23-27 July 2018.
Daria J. Hazuda1; Min Xu2; Winnie Ngo1; Meizhen Feng1; Carey Hwang3; Jay A. Grobler1; Ming-Tain Lai1
1Department of Antiviral Research, 2Department of Pharmacology, 3Department of Clinical Research, Merck Research Laboratories (West Point, PA), Merck & Co., Inc., Kenilworth, NJ, USA
![0730181](../images%20/073018/073018-1/0730181.gif)
![0730182](../images%20/073018/073018-1/0730182.gif)
![0730183](../images%20/073018/073018-1/0730183.gif)
![0730184](../images%20/073018/073018-1/0730184.gif)
![0730185](../images%20/073018/073018-1/0730185.gif)
![0730186](../images%20/073018/073018-1/0730186.gif)
![0730187](../images%20/073018/073018-1/0730187.gif)
![0730188](../images%20/073018/073018-1/0730188.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|